Grey Matters Health Inc. (AGNPF)
OTC Markets OTCPK
Fundamentals
Valuation and ratings
Grey Matters Health Inc. trades at USD0.29. We do not hold enough of the inputs to run a discounted cash flow on this company, so we publish no fair value for it rather than a number we would not defend.
About Grey Matters Health Inc.
Grey Matters Health Inc. operates as a clinical stage pharmaceutical development company in Canada and Australia. The company focuses on developing the therapeutic drugs in the areas of non-alcoholic steatohepatitis, liver disease, chronic kidney disease, and stroke program. Its pipeline includes repirinast for the treatment of chronic kidney disease; and N,N-Dimethyltryptamine for the treatment of strokes and traumatic brain injuries. The company was formerly known as Algernon Health Inc. and changed its name to Grey Matters Health Inc. in April 2026. Algernon Health Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.
The full research page for AGNPF, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.